Sarinj Fattah1, Abhijit Babaji Shinde2, Maja Matic3,4, Myriam Baes2, Ron H N van Schaik3, Karel Allegaert4,5, Celine Parmentier6, Lysiane Richert6,7, Patrick Augustijns1, Pieter Annaert8. 1. Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Campus Gasthuisberg O&N II Herestraat 49 Box 921, 3000, Leuven, Belgium. 2. Laboratory of Cell Metabolism, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. 3. Department Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, Netherlands. 4. Intensive Care and Department of Surgery, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands. 5. Department of Development and Regeneration, KU Leuven, Leuven, Belgium. 6. KaLy-Cell, Plobsheim, France. 7. Université de Franche-Comté, 4267, Besançon, EA, France. 8. Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Campus Gasthuisberg O&N II Herestraat 49 Box 921, 3000, Leuven, Belgium. pieter.annaert@kuleuven.be.
Abstract
PURPOSE: OCT1/3 (Organic Cation Transporter-1 and -3; SLC22A1/3) are transmembrane proteins localized at the basolateral membrane of hepatocytes. They mediate the uptake of cationic endogenous compounds and/or xenobiotics. The present study was set up to verify whether the previously observed variability in OCT activity in hepatocytes may be explained by inter-individual differences in OCT1/3 mRNA levels or OCT1 genotype. METHODS: Twenty-seven batches of cryopreserved human hepatocytes (male and female, age 24-88 y) were characterized for OCT activity, normalized OCT1/3 mRNA expression, and OCT1 genetic mutation. ASP+ (4-[4-(dimethylamino)styryl]-N-methylpyridinium iodide) was used as probe substrate. RESULTS: ASP+ uptake ranged between 75 ± 61 and 2531 ± 202 pmol/(min × million cells). The relative OCT1 and OCT3 mRNA expression ranged between 0.007-0.46 and 0.0002-0.005, respectively. The presence of one or two nonfunctional SLC22A1 alleles was observed in 13 batches and these exhibited significant (p = 0.04) association with OCT1 and OCT3 mRNA expression. However, direct association between genotype and OCT activity could not be established. CONCLUSION: mRNA levels and genotype of OCT only partially explain inter-individual variability in OCT-mediated transport. Our findings illustrate the necessity of in vitro transporter activity profiling for better understanding of inter-individual drug disposition behavior.
PURPOSE:OCT1/3 (Organic Cation Transporter-1 and -3; SLC22A1/3) are transmembrane proteins localized at the basolateral membrane of hepatocytes. They mediate the uptake of cationic endogenous compounds and/or xenobiotics. The present study was set up to verify whether the previously observed variability in OCT activity in hepatocytes may be explained by inter-individual differences in OCT1/3 mRNA levels or OCT1 genotype. METHODS: Twenty-seven batches of cryopreserved human hepatocytes (male and female, age 24-88 y) were characterized for OCT activity, normalized OCT1/3 mRNA expression, and OCT1 genetic mutation. ASP+ (4-[4-(dimethylamino)styryl]-N-methylpyridinium iodide) was used as probe substrate. RESULTS:ASP+ uptake ranged between 75 ± 61 and 2531 ± 202 pmol/(min × million cells). The relative OCT1 and OCT3 mRNA expression ranged between 0.007-0.46 and 0.0002-0.005, respectively. The presence of one or two nonfunctional SLC22A1 alleles was observed in 13 batches and these exhibited significant (p = 0.04) association with OCT1 and OCT3 mRNA expression. However, direct association between genotype and OCT activity could not be established. CONCLUSION: mRNA levels and genotype of OCT only partially explain inter-individual variability in OCT-mediated transport. Our findings illustrate the necessity of in vitro transporter activity profiling for better understanding of inter-individual drug disposition behavior.
Entities:
Keywords:
Organic Cation Transporter (OCT); drug uptake transporters; fluorescent probe substrate; human hepatocytes; mRNA expression and genetic polymorphism
Authors: M V Tzvetkov; S V Vormfelde; D Balen; I Meineke; T Schmidt; D Sehrt; I Sabolić; H Koepsell; J Brockmöller Journal: Clin Pharmacol Ther Date: 2009-06-17 Impact factor: 6.875
Authors: Mikko Niemi; Katja A Arnold; Janne T Backman; Marja K Pasanen; Ute Gödtel-Armbrust; Leszek Wojnowski; Ulrich M Zanger; Pertti J Neuvonen; Michel Eichelbaum; Kari T Kivistö; Thomas Lang Journal: Pharmacogenet Genomics Date: 2006-11 Impact factor: 2.089
Authors: Patrik Lundquist; Johan Lööf; Anna-Karin Sohlenius-Sternbeck; Eva Floby; Jenny Johansson; Johan Bylund; Janet Hoogstraate; Lovisa Afzelius; Tommy B Andersson Journal: Drug Metab Dispos Date: 2014-01-06 Impact factor: 3.922
Authors: Maciej J Zamek-Gliszczynski; Hao Xiong; Nita J Patel; Ryan Z Turncliff; Gary M Pollack; Kim L R Brouwer Journal: J Pharmacol Exp Ther Date: 2003-02 Impact factor: 4.030
Authors: Anne T Nies; Mikko Niemi; Oliver Burk; Stefan Winter; Ulrich M Zanger; Bruno Stieger; Matthias Schwab; Elke Schaeffeler Journal: Genome Med Date: 2013-01-11 Impact factor: 11.117